Alaunos Therapeutics, Inc. (TCRT) — Institutional Holders, Q2 2026
29 institutional investment managers reported a TCRT position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $204.4K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
TCRT in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- CITADEL ADVISORSAdded · +1,351 sh+$3.1K
- SRS Capital AdvisorsNew · +1,216 sh+$2.7K
- WELLS FARGO & COMPANYAdded · +198 sh+$447.00
- ROYAL BANK OF CANADAAdded · +190 sh+$429.00
- MORGAN STANLEYAdded · +183 sh+$414.00
Biggest sellers
- HRT FINANCIALSold out · -13,327 sh-$30.1K
- TWO SIGMA INVESTMENTSSold out · -10,839 sh-$24.5K
- XTX Topco LtdSold out · -10,174 sh-$23.0K
- GEODE CAPITAL MANAGEMENTTrimmed · -3,204 sh-$7.2K
- UBS Group AGTrimmed · -1,282 sh-$2.9K
TCRT 13F holders ranked 1–29 of 29
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | BlackRock#1 · 21,353 sh | 21,353 | $48.3K | 0.00% | 0.0% |
| 2 | GEODE CAPITAL MANAGEMENT#2 · 19,356 sh | 19,356 | $43.8K | 0.00% | -14.2% |
| 3 | VANGUARD FIDUCIARY#3 · 15,497 sh | 15,497 | $35.0K | 0.00% | 0.0% |
| 4 | VANGUARD CAPITAL MANAGEMENT#4 · 14,063 sh | 14,063 | $31.8K | 0.00% | 0.0% |
| 5 | CITADEL ADVISORS#5 · 11,870 sh | 11,870 | $26.8K | 0.00% | +12.8% |
| 6 | OSAIC#6 · 1,731 sh | 1,731 | $3.9K | 0.00% | -2.7% |
| 7 | Tower Research Capital (TRC)#7 · 1,621 sh | 1,621 | $3.7K | <0.01% | +2.4% |
| 8 | SRS Capital Advisors#8 · 1,216 sh | 1,216 | $2.7K | 0.00% | New |
| 9 | UBS Group AG#9 · 992 sh | 992 | $2.2K | 0.00% | -56.4% |
| 10 | MORGAN STANLEY#10 · 836 sh | 836 | $1.9K | 0.00% | +28.0% |
| 11 | Vanguard Global Advisers#11 · 501 sh | 501 | $1.1K | 0.00% | 0.0% |
| 12 | ROYAL BANK OF CANADA#12 · 375 sh | 375 | $1.0K | 0.00% | +102.7% |
| 13 | WELLS FARGO & COMPANY#13 · 388 sh | 388 | $877.00 | 0.00% | +104.2% |
| 14 | Ronald Blue#14 · 135 sh | 135 | $305.00 | — | 0.0% |
| 15 | Steward Partners Investment Advisory#15 · 112 sh | 112 | $253.00 | 0.00% | +21.7% |
| 16 | Federation des caisses Desjardins du Quebec#16 · 70 sh | 70 | $158.00 | 0.00% | 0.0% |
| 17 | BOKF, NA#17 · 66 sh | 66 | $149.00 | — | New |
| 18 | Axiom Investment Management#18 · 46 sh | 46 | $104.00 | <0.01% | New |
| 19 | Key FInancial#19 · 24 sh | 24 | $54.00 | 0.00% | 0.0% |
| 20 | SIGNATUREFD#20 · 23 sh | 23 | $52.00 | — | 0.0% |
| 21 | Newbridge Financial Services Group#21 · 21 sh | 21 | $47.00 | — | 0.0% |
| 22 | NBC SECURITIES#22 · 20 sh | 20 | $45.00 | — | 0.0% |
| 23 | AdvisorNet Financial#23 · 19 sh | 19 | $43.00 | — | 0.0% |
| 24 | BARCLAYS PLC#24 · 15 sh | 15 | $34.00 | 0.00% | New |
| 25 | WEST PACES ADVISORS#25 · 10 sh | 10 | $23.00 | — | New |
| 26 | Inspire Investing#26 · 9 sh | 9 | $20.00 | — | 0.0% |
| 27 | BNP PARIBAS FINANCIAL MARKETS#27 · 6 sh | 6 | $14.00 | 0.00% | 0.0% |
| 28 | IFG Advisory#28 · 6 sh | 6 | $14.00 | 0.00% | New |
| 29 | Tidemark#29 · 2 sh | 2 | $5.00 | 0.00% | 0.0% |
Funds that sold out of TCRT in Q2 2026 (4)
Held TCRT at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| HRT FINANCIAL13,327 sh | 13,327 | $38.0K |
| TWO SIGMA INVESTMENTS10,839 sh | 10,839 | $31.0K |
| XTX Topco Ltd10,174 sh | 10,174 | $29.1K |
| CITIGROUP1 sh | 1 | $3.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.